| VIS ID | Virus | Ensembl ID | Gene Type | Target Gene | Oncogene | Tumor Suppressor Gene | NCBI ID | Uniprot ID |
|---|---|---|---|---|---|---|---|---|
| TVIS10006400 | HBV | ENSG00000006071.16 | protein_coding | ABCC8 | No | No | 6833 | Q09428 |
| TVIS10014476 | HBV | ENSG00000006071.16 | protein_coding | ABCC8 | No | No | 6833 | Q09428 |
| TVIS20010586 | HPV | ENSG00000006071.16 | protein_coding | ABCC8 | No | No | 6833 | Q09428 |
| TVIS44004571 | HTLV-1 | ENSG00000006071.16 | protein_coding | ABCC8 | No | No | 6833 | Q09428 |
| TVIS44020396 | HTLV-1 | ENSG00000006071.16 | protein_coding | ABCC8 | No | No | 6833 | Q09428 |
Target Gene Table
▼
TCGA Plot Options
▼
Drug Information
▼
| Gene | ABCC8 |
|---|---|
| DrugBank ID | DB00912 |
| Drug Name | Repaglinide |
| Target ID | BE0000207 |
| UniProt ID | Q09428 |
| Regulation Type | inhibitor |
| PubMed IDs | 10773014; 11716850; 12196472; 15219283; 15380228; 11728565 |
| Citations | Hu S, Wang S, Fanelli B, Bell PA, Dunning BE, Geisse S, Schmitz R, Boettcher BR: Pancreatic beta-cell K(ATP) channel activity and membrane-binding studies with nateglinide: A comparison with sulfonylureas and repaglinide. J Pharmacol Exp Ther. 2000 May;293(2):444-52.@@Sunaga Y, Gonoi T, Shibasaki T, Ichikawa K, Kusama H, Yano H, Seino S: The effects of mitiglinide (KAD-1229), a new anti-diabetic drug, on ATP-sensitive K+ channels and insulin secretion: comparison with the sulfonylureas and nateglinide. Eur J Pharmacol. 2001 Nov 9;431(1):119-25.@@Hansen AM, Christensen IT, Hansen JB, Carr RD, Ashcroft FM, Wahl P: Differential interactions of nateglinide and repaglinide on the human beta-cell sulphonylurea receptor 1. Diabetes. 2002 Sep;51(9):2789-95.@@Wangler B, Schneider S, Thews O, Schirrmacher E, Comagic S, Feilen P, Schwanstecher C, Schwanstecher M, Shiue CY, Alavi A, Hohnemann S, Piel M, Rosch F, Schirrmacher R: Synthesis and evaluation of (S)-2-(2-[18F]fluoroethoxy)-4-([3-methyl-1-(2-piperidin-1-yl-phenyl)-butyl-carbam oyl]-methyl)-benzoic acid ([18F]repaglinide): a promising radioligand for quantification of pancreatic beta-cell mass with positron emission tomography (PET). Nucl Med Biol. 2004 Jul;31(5):639-47.@@Wangler B, Beck C, Shiue CY, Schneider S, Schwanstecher C, Schwanstecher M, Feilen PJ, Alavi A, Rosch F, Schirrmacher R: Synthesis and in vitro evaluation of (S)-2-([11C]methoxy)-4-[3-methyl-1-(2-piperidine-1-yl-phenyl)-butyl-carbamoyl]-be nzoic acid ([11C]methoxy-repaglinide): a potential beta-cell imaging agent. Bioorg Med Chem Lett. 2004 Oct 18;14(20):5205-9.@@Dornhorst A: Insulinotropic meglitinide analogues. Lancet. 2001 Nov 17;358(9294):1709-16. |
| Groups | Approved; Investigational |
| Direct Classification | Phenylpiperidines |
| SMILES | CCOC1=C(C=CC(CC(=O)N[C@@H](CC(C)C)C2=CC=CC=C2N2CCCCC2)=C1)C(O)=O |
| Pathways | Repaglinide Action Pathway |
| PharmGKB | PA451234 |
| ChEMBL | CHEMBL1272 |
